Operation for N2 small cell lung carcinoma

Salzer, G; Müller, Ludwig; Huber, H.; Denz, H.; Gasser, R.; Frommhold, H; Ebner, Ingrid

doi:10.1016/0003-4975(90)90016-y

Cited by 36 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year survival rate for all 46 patients was 46% and in the 32 completely resected patients the 5-year survival was 63% with 100% local control. Five-year survival rates in the range of 40% have also been reported by the Toronto Group and the Innsbruck Group with the use of combined modality treatment utilizing surgery as an adjunct [79,83].…”

Section: Induction Chemotherapy or Radiotherapy Followed By Surgerymentioning

confidence: 84%

“…Long-term survival rates of up to 70% for stage I disease and 20-30% for stage II and III tumors have been reported following surgery and postoperative chemotherapy [76][77][78]. The presence of nodal involvement indicates a poor prognostic subset, although a 5-year survival rate of 20-25% has been reported for patient with N2 disease treated by surgery and adjuvant chemotherapy [79][80][81]. With surgery alone, long-term survival is rare with N1 disease and has not been reported with N2 disease [72,73].…”

Section: Surgery Followed By Chemotherapy And/or Radiotherapymentioning

confidence: 99%

“…Adjuvant surgery may help to remove all the tumor cells at the primary sites, including resistant residual malignant cells and any possible non-small cell malignant component. Reports show that it is not uncommon for resected tumors to contain no evidence of a SCLC component, but to contain persisting elements of non-small cell malignancy [68,79,83]. The clinical impact of such surgery is unproven, particularly as the majority of patients with residual local disease will also have occult metastatic spread.…”

Section: Induction Chemotherapy or Radiotherapy Followed By Surgerymentioning

confidence: 99%

See 2 more Smart Citations

Management of small cell lung cancer

Yip

Karapetis

Steer

2001

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Small cell lung cancer is a tumor that has a very poor prognosis without treatment. It is however, highly responsive to chemotherapy and radiotherapy. Pretreatment clinical and laboratory parameters--in addition to staging--can prognosticate outcome and help define the aim of treatment. Different schedules of chemotherapy have been developed and varied strategies, such as chemotherapy dose intensification have been tried to improve outcomes. New agents, such as irinotecan, gemcitabine and topotecan have also been tested. Clinical trials have helped to define strategies of integrating thoracic radiotherapy and prophylactic cranial radiotherapy into management of those patients with limited disease to improve survival further. Despite good initial responses to treatment, most patients eventually relapse. Maintenance strategies with ongoing chemotherapy or novel agents, such as interferon, matrix metalloproteinase inhibitors, thalidomide and vaccines are discussed.

show abstract

Section: Induction Chemotherapy or Radiotherapy Followed By Surgerymentioning

confidence: 84%

Section: Surgery Followed By Chemotherapy And/or Radiotherapymentioning

confidence: 99%

Section: Induction Chemotherapy or Radiotherapy Followed By Surgerymentioning

confidence: 99%

See 1 more Smart Citation

Management of small cell lung cancer

Yip

Karapetis

Steer

2001

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

“…Patients with lesions that are found to be stage II at thoracotomy should receive postoperative adjuvant therapy. Some preliminary data suggest that patients with preoperative evidence of N1 or minimal N2 disease benefit from induction chemotherapy and adjuvant surgery (62,63). It should be stressed that chemotherapy remains the primary treatment for SCLC, and surgery may be used as an alternative to radiotherapy for local control, in some cases under strict investigational protocols only.…”

Section: Staging Sclcmentioning

confidence: 99%

Staging Lung Cancer: Current Controversies and Strategies

Karmy‐Jones

Hyland

Lewis

et al. 1997

Canadian Respiratory Journal

View full text Add to dashboard Cite

A consistent approach to staging is required for the rational management of lung cancer. This paper was prepared at the request of the Standards Committee of the Canadian Thoracic Society, and reviews and discusses the relative merits of the available methods of staging. Whichever methods are chosen by a particular institution, the following points must be stressed. No patient can be considered automatically "unresectable" when chest radiography and/ or computed tomography demonstrate adenopathy or only suggest local invasion. Clinical and/or radiographical evidence suggesting extensive local or metastatic disease should be evaluated as completely as possible before subjecting the patient to a possible "nontherapeutic" thoracotomy. Finally, in some cases thoracotomy is required to decide whether the lesion is "completely" resectable.

show abstract

“…Several studies (8)(9)(10)(11)(12) have retrospectively analyzed the prognosis and survival of patients with LD-SCLC after surgery, involving a small number of patients with p-N2. We collected a large number of cases of p-N2 LD-SCLC patients diagnosed through surgery.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer

Qiao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The benefits of surgical resection for patients with stage N2 limited-disease small-cell lung cancer (LD-SCLC) remain controversial. This retrospective study analyzed the survival and recurrence patterns of the patients diagnosed with pathological N2 (p-N2) LD-SCLC after radical resection. A total of 171 p-N2 LD-SCLC patients who underwent radical pulmonary resection and systematic lymphadenectomies at Shanghai Chest Hospital from July 2005 to June 2015 were enrolled. The influence of the mediastinal lymph node status (single or multiple nodes, single- or multiple-station) on the survival and recurrence patterns was retrospectively analyzed. The main recurrence sites were outside the chest cavity (54.8%) and hematogenous metastasis (67.4%). The bone and liver as initial recurrence sites had a poor prognosis, with a median overall survival (OS) of 13.100 months and 11.900 months, respectively. The median disease-free survival (DFS) of patients diagnosed with single and multiple p-N2 after surgery were 19.233 and 9.367 months (P = 0.001), and the median OS were 43.033 and 17.100 months (P < 0.001), respectively. In conclusion, recurrence occurred in the form of hematogenous metastasis mostly in the extra-thoracic part. Interestingly, patients diagnosed with single p-N2 benefited from radical resection. Surgery may be a treatment option regardless of the T stage if N2 SCLC with a single metastatic lymph node can be identified preoperatively.

show abstract

Operation for N2 small cell lung carcinoma

Cited by 36 publications

References 17 publications

Management of small cell lung cancer

Management of small cell lung cancer

Staging Lung Cancer: Current Controversies and Strategies

Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer

Contact Info

Product

Resources

About